Yesterday, Catalent, Inc.,  a specialist in advanced delivery technologies and development solutions for drugs, biologics and consumer health products,  launched its initial public offering of 42,500,000 shares of its common stock at $20.50 per share. The shares began trading on the New York Stock Exchange yesterday under the ticker symbol “CTLT,” and the offering is expected to close on August 5, 2014, subject to customary closing conditions. For an interview with the company’s CEO, on Th...